What drove the quarterly revenue growth for Botanix Pharmaceuticals (ASX:BOT)?

Botanix Pharmaceuticals (ASX:BOT) generated $10.1 million in Q4 FY26 net revenue primarily due to higher demand for its topical gel Sofdra. Total prescription shipments grew 25% sequentially to 33,358 units, supported by an improved average gross-to-net yield of 22%.

How did the financial metrics for Botanix Pharmaceuticals (ASX:BOT) perform in Q4 FY26?

Botanix Pharmaceuticals (ASX:BOT) recorded gross sales of $46.7 million and reduced its operating cash outflow to $10.6 million for the quarter. The company ended the period on June 30 with $36.6 million in cash reserves following capital raise receipts.

How did the share price of Botanix Pharmaceuticals (ASX:BOT) react to the announcement?

The share price of Botanix Pharmaceuticals (ASX:BOT) fell 4.35% to $0.021 following the market release. This drop occurred despite the company reporting a 45% sequential increase in quarterly net revenue.

What specific product is commercialised by Botanix Pharmaceuticals (ASX:BOT)?

Botanix Pharmaceuticals (ASX:BOT) commercialises Sofdra, an FDA-approved topical gel formulated for the treatment of primary axillary hyperhidrosis, or excessive underarm sweating. Monthly shipments of the gel reached a record high of 12,895 units in June 2026.

What is the forward commercial strategy for Botanix Pharmaceuticals (ASX:BOT)?

Botanix Pharmaceuticals (ASX:BOT) stated that it expects sales momentum for Sofdra to continue as US healthcare insurance deductibles normalise. The company completed a $45 million capital raise during the fiscal year to fund its ongoing commercial expansion.

Image for illustrative purposes only. Not a real photo.

Botanix Pharmaceuticals reports $10.1M quarterly net revenue

Written by Liezl GambePublished Jul 27, 2026, 4:58 AM

· Botanix Pharmaceuticals delivered Q4 net revenue of $10.1 million, representing a 45% sequential increase.

· The company's share price fell 4.35% to $0.022 despite the revenue growth.

· Growth was driven by expanding Sofdra prescription volume and higher gross-to-net yields.

Botanix Pharmaceuticals (ASX:BOT) generated $10.1 million in net revenue for the fourth quarter of fiscal 2026.

This result represents a 45% increase from the $6.9 million reported in the previous quarter.

Gross sales for the period rose to $46.7 million as prescription shipments reached 33,358 units.

Botanix stated that operating cash outflow improved to $10.6 million while cash reserves reached $36.6 million.

Following the announcement, the Botanix Pharmaceuticals share price was down at $0.021.

The company develops and sells Sofdra, an FDA-approved topical gel for excessive underarm sweating.

Earlier in the fiscal year, Botanix completed a capital raise to support its commercial platform expansion.

Botanix Pharmaceuticals reports $10.1M quarterly net revenue

Frequently asked questions

Assets related to this article